Pharmacoeconomics in HP-related diseases: More questions than answers

Acta Gastro-Enterologica Belgica

Volumn 61, Issue 3, 1998, Pages 352-356

  Deltenre, M ^a   De Bruyne, I ^a   Jonas, C ^a   De Koster, E ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Gastric cancer; Helicobacter pylori; Peptic ulcer; Pharmacoeconomics; Treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH DERIVATIVE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE DERIVATIVE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSPEPSIA; GASTROINTESTINAL DISEASE; HELICOBACTER PYLORI; HUMAN; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; STOMACH CANCER;

ANTI-ULCER AGENTS; COST OF ILLNESS; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MODELS, ECONOMIC; OMEPRAZOLE; RANITIDINE; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 0031718653     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. BLOMQVIST A. Productivity and technology change in health care. Pharmacoeconomics, 1994, 5 : 1-7.
2. JONSSON B. Economic evaluation of new medical technology. Scand. J Gastroenterol., 1994. 201 ; 87-90.
3. JONSSON B., KARLSSON G. Economic evaluation in gastrointestinal disease Scand. J. Gastroenterol., 1996, S31 ; 44-51.
4. MIGNON M., PENSTON J.G., DELTENRE M., RUSZNIEWSKI P., DOBRILLA G. Natural History of Duodenal Ulcer disease : are we at a Turning Point ? Gastroenterol International, 1994, 7 ; 95-113.
5. SONNENBERG A., EVERHART J.E. Current prevalence rates and risk factors of peptic ulcer in the United States. Proceedings of Digestive Disease Week. 1995, A-782 (Abstract).
6. PENSTON J.G. The efficacy and safety of long-term maintenance treatment of duodenal ulcer with ranitidine. Scand J Gastroenterol., 1990, 25 (Suppl. 177) 1-104
7. GASTARD J., BRETAGNE J.F, RAOUL J.L., COTTEREAU J. Histoire Naturelle de l'ulcère gastro-duodénal In : Progrès en Hépatogastroentérologie. La Maladie Ulcéreuse. (Dive Ch. Ed.) 1990, Doin, Paris, 1-6.
8. BLOOM B.S. Cross-national changes in the effects of peptic ulcer disease. Ann. Int. Med., 1991, 114 : 558-62.
9. JONSSON B., CARLSSON P. The effects of cimetidine on the cost of ulcer disease in Sweden. Soc. Sci. Med., 1991, 33 ; 275-82.
10. PYM B , SANDSTAD J., SEVILLE P., BYTH K., MIDDLETON W.R., TALLEY N.J , PIPER D.W Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology, 1990, 99 ; 27-35.
11. Peptic ulcer medication usage US 1989 Stat. Bull. Metrop. Insur. Co., 1990, 71 (4) : 10-7.
12. CAMPBELL L M The role of a Helicobacter pylon eradication regimen (omeprazole plus amoxycillin) in the long-term management of ulcer-like dyspepsia in general practice. Br. J Med. Econ., 1994, 7/II 147-153.
13. COTTRILL M.R.B The prevalence of Helicobacter pylon infection in patients receiving long-term H2-receptor antagonists in general practice : Clinical and financial consequences of eradication using omeprazole plus amoxycillin or "triple therapy". Br. J. Med. Econ., 1994, 7/I: 35-41
14. POWELL K.U., BELL G.D., BOLTON G H , BURRIDGE S.M., BOWDEN A.F., RAMEH B , HART L., BRADLEY P, HARRISON G., GANT P.W Helicobacter pylori eradication in patients with peptic ulcer disease Clinical consequences and financial implications. Q. J Med., 1994, 87 . 283-290.
15. DELTENRE M., ILUNGA K.O Helicobacter pylori eradication in duodenal ulcer disease is costbeneficial ; a Belgian model. J. Phys. Pharmacol., 1997, 48 : 107-114.
16. SONNENBERG A., BECK J. Markov models in medical decision making . a practical guide. Medical Decision Making, 1993, 13: 322-38.
17. O'BRIEN B., GOEREE R., HAFEEZ M., HUNT R.H. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Int. Med., 1995, 155 : 1958-1963.
18. BELL G., POWELL K., BOLTON G., RICHARDSON P. Clinical and pharmacoeconomic evaluation of management strategies for duodenal ulcer disease Br. J. Med. Econ., 1993, 6 : 45-58.
19. LABENZ J., BLUM A.L., BAYERDORFFER E., MEINING A., STOLTE M., BORSCH G. Curing Helicobacter pylon infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology, 1997, 112 : 1442-1447.
20. DELTENRE M., JONSSON B. Pharmacoeconomics. In : MALFERTHEINER P., MÉGRAUD F., MICHETTI P. and PRICE A. (Editors). The year in Helicobacter pylori. Rapid Science Publishers. Current opinion in gastroenterology, 1996, 12 (Suppl. 1) : 45-49.
21. SONNENBERG A., TOWNSEND W F. Costs of duodenal ulcer therapy with antibiotics. Arch, Int Med., 1995, 155 : 922-28.
22. VAKIL N., FENNERTY M.B. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylon in duodenal ulcer. Am. J Gastroenterol., 1996, 91 239-245
23. JÖNSSON B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand. J. Gastroenterol., 1996. 31 (Suppl. 215) : 90-95
24. BAZZOLI F., ZAGARI R.M., FOSSI S., POZZATO P., ALAMPI P., SIMONI P. et al. Short-term low-dose triple therapy for eradication of Helicobacter pylori. Eur. J. Gastroenterol Hepatol, 1994, 6 ; 773-777
25. TREIBER G. PENSTON J G., MCCOLL K.E.L Eradication of Helicobacter pylori : An objective assessment of current therapies Br J. Clin. Pharmacol., 1997, 43/3 : 223-243. The influence of drug dosage on the Helicobacter pylori eradication : a cost-effectiveness analysis. Am. J. Gastroenterol, 1996, 91 ; 246-247.
26. TREIBER G. PENSTON J G., MCCOLL K.E.L Eradication of Helicobacter pylori : An objective assessment of current therapies Br J. Clin. Pharmacol., 1997, 43/3 : 223-243. The influence of drug dosage on the Helicobacter pylori eradication : a cost-effectiveness analysis. Am. J. Gastroenterol, 1996, 91 ; 246-247.
27. TAYLOR J.L., ZAGARI M., MURPHY K., FRESTON J.W. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylon. Arch. Intern. Med., 1997. 157/I : 87-97.
28. PENSTON J.G., MCCOLL K E.L. Eradication of Helicobacter pylori ; An objective assessment of current therapies. Br J. Clin. Pharmacol., 1997, 43/3 : 223-243.
29. DELTENRE M., JONAS C., VAN GOSSUM M., BUSET M., OTERO J., DE KOSTER E Omeprazole-based antimicrobial therapies : results in 198 Helicobacter pylori-positive patients. Eur. J. Gastroenterol. Hepatol., 1995, 7 (Suppl. 1) : S39-S44.
30. JONAS C., DE REUCK M., OTERO J., VAN GOSSUM M., DELTENRE M. Low-dose, one-week triple therapies for HP : a randomized study. Acta Gastroenterol. Belg., 1996, 59 : C48.
31. DELTENRE M., JONAS C., OTERO J., COZZOLI A, DENIS P, BURETTE A., DE KOSTER E Strategies for Helicobacter pylori eradication in 1995 : a review of international and Belgian experience. J. Physiol. Pharmacol., 1996, 47, 59-69.
32. PARSONNET J., VANDERSTEEN D., GOATES J., SIBLEY R.K., PRITIKJN J., CHANG Y Helicobacter pylori in intestinal and diffusetype gastric adenocarcinomas. J. Natl. Cancer Inst., 1991, 83 640-643.
33. DE KOSTER E., BUSET M., FERNANDES E , DELTENRE M. Helicobacter pylori . The link with gastric cancer Eur. J. Cancer Prev., 1994, 3/3 : 247-257.
34. FORMAN D. The prevalence of Helicobacter pylori infection in gastric cancer. Aliment. Pharmacol. Ther. Suppl., 1995, 9/2 : 71-76.
35. BAYERDORFFER E., NEUBAUER A , RUDOLF B., THIEDE C., LEHN N , EIDT S., STOLTE M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet, 1995, 1591-1594.
36. PARSONNKT J. Can gastric cancer be prevented by control of H. pylon infection ? Personnal Communication 4th United European Gastroenterology Week. Berlin, 1995, 17-21st September.
37. PARSONNET J., HARRIS R.A., HACK H M , OWENS D.K. Modelling cost-effectiveness of Helicobacter pylon screening to prevent gastric cancer. A mandate for clinical trials Lancet, 1996, 348/9021, 150-154.
38. MOAYYEDI P., DIXON M F. Significance of Helicobacter pylori infection and gastric cancer. Implications for screening. Gastrointest. Endosc Clin. North AM., 1997, 7/1 . 47-64.
39. HOLMES J.K. Patterns of prescribing in Irish general practitioners Ir. Med. J , 1992,85 : 154-6.
40. JONES R.H. Clinical economics review : Gastrointestinal disease in primary care. Aliment. Pharmacol Ther., 1996, 10/3 ; 233-239
41. BERNERSEN B., JOHNSEN R , STRAUME B. Non-ulcer dyspepsia and peptic ulcer : The distribution in a population and their relation to risk factors. Gut, 1996. 38/6 . 822-825.
42. VERDU E.F., FRASER R., TIBERIO D., HERRANZ M., SIPPONEN P., BLUM A.L., MICHETTI P. Prevalence of Helicobacter pylori infection and chronic dyspeptic symptoms among immigrants from developing countries and people born in industrialized countries. Digestion, 1996, 57/3 : 180-185.
43. SONNENBERG A Cost-benefit analyis of testing for Helicobacter pylori in dyspeptic subjects. Am. J. Gastroenterol., 1996, 91 : 1773-1777.
44. OLSON A.D., FENDRICK A.M., DEUTSCH D., CHERNEW M.E , HIRTH R.A., PATEL C., BLOOM B.S. Evaluation of initial noninvasive therapy in pediatric patients presenting with suspected ulcer disease. Gastrointest. Endosc., 1996, 44/5 : 554-561.
45. OFMAN J.J., ETCHASON J., FULLERTON S., KAHN K.L., SOIL A.H. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia : Clinical and economic consequences. Ann. Intern. Med., 1997, 126/4 : 280-291.
46. BYTZER P., HANSEN J.M., SCHAFFALITZKY DE MUCKADELL O B. Empincal H-2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994, 343/8901: 811-816.
47. GREENBERG P.D., KOCH J., CELLO J.P. Clinical utility and cost effectiveness of Helicobacter pylori testing for patients with duodenal and gastric ulcers. Am J. Gastroenterol., 1996, 91 : 228-232.
48. KOLTS B E., JOSEPH B., ACHEM S.R., BIANCHI T., MONTEIRO C. Helicobacter pylori detection ; A quality and cost analysis. Am. J. Gastroenterol, 1993, 88 : 650-655.
49. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. P. Malfertheiner, F Megraud, C. O'Moram. D. Bell, G. Bianchi Porro. M. Deltenre. D. Forman, G. Gasbarrini, B. Jaup, J. J. Misiewicz, J. Pajares, M. Quina and E. Rauws European Journal of Gastroenterology & Hepatology, 1997, 9 : 1-2.
50. OBERENDER P. Therapeutical opportunities for Helicobacter pylon ; the adequate therapy from an economic view. Leber Magen Darm. 1997, 27/1 : 30-34.